A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT07043400 · RECRUITING
Trial details
- NCT number
- NCT07043400
- Sponsor
- BeOne Medicines
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-27
- Primary completion
- 2027-10-30
- Enrollment
- 351
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.